Roche has signed a definitive merger agreement for the acquisition of clinical-stage biopharmaceutical company 89bio, for a total equity value of around $2.4bn. Under the deal, Roche will initiate a tender offer to purchase all outstanding shares of 89bio common stock at$14.50 per share in cash. This will also include a non-tradeable contingent value right (CVR) that could yield payments of up to $6 per share based on specific milestones. The potential total deal value represents up to$3.5bn. The off ...